BlackRock
AVIR icon

BlackRock’s Atea Pharmaceuticals AVIR Stock Holding History

BlackRock’s Portfolio AVIR Stock Details AVIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$40.5M Buy
8,720,077
+284,640
+3% +$1.42M ﹤0.01% 2809
2026
Q1 		$45.4M Sell
8,435,437
-55,765
-0.7% -$256K ﹤0.01% 2569
2025
Q4 		$30.3M Buy
8,491,202
+31,982
+0.4% +$102K ﹤0.01% 2836
2025
Q3 		$24.5M Sell
8,459,220
-209,307
-2% -$715K ﹤0.01% 2962
2025
Q2 		$31.2M Sell
8,668,527
-274,538
-3% -$819K ﹤0.01% 2760
2025
Q1 		$26.7M Sell
8,943,065
-119,116
-1% -$372K ﹤0.01% 2765
2024
Q4 		$30.4M Buy
9,062,181
+71,447
+0.8% +$237K ﹤0.01% 2780
2024
Q3 		$30.1M Sell
8,990,734
-129,829
-1% -$471K ﹤0.01% 2783
2024
Q2 		$30.2M Sell
9,120,563
-122,743
-1% -$458K ﹤0.01% 2730
2024
Q1 		$37.3M Sell
9,243,306
-200,581
-2% -$785K ﹤0.01% 2625
2023
Q4 		$28.8M Buy
9,443,887
+1,252,385
+15% +$3.79M ﹤0.01% 2802
2023
Q3 		$24.6M Buy
8,191,502
+482,789
+6% +$1.64M ﹤0.01% 2827
2023
Q2 		$28.8M Sell
7,708,713
-333,023
-4% -$1.25M ﹤0.01% 2802
2023
Q1 		$26.9M Buy
8,041,736
+8,164
+0.1% +$33.1K ﹤0.01% 2820
2022
Q4 		$38.6M Buy
8,033,572
+162,451
+2% +$822K ﹤0.01% 2646
2022
Q3 		$44.8M Buy
7,871,121
+463,579
+6% +$3.55M ﹤0.01% 2524
2022
Q2 		$52.6M Buy
7,407,542
+782,849
+12% +$5.34M ﹤0.01% 2458
2022
Q1 		$47.8M Buy
6,624,693
+843,496
+15% +$5.73M ﹤0.01% 2621
2021
Q4 		$51.7M Buy
5,781,197
+1,644,396
+40% +$25.6M ﹤0.01% 2644
2021
Q3 		$145M Buy
4,136,801
+645,838
+19% +$17.9M ﹤0.01% 1957
2021
Q2 		$75M Buy
3,490,963
+2,415,459
+225% +$72.6M ﹤0.01% 2437
2021
Q1 		$66.4M Sell
1,075,504
-240,326
-18% -$16.2M ﹤0.01% 2438
2020
Q4 		$55M Buy
+1,315,830
New +$42.4M ﹤0.01% 2413

Other funds holding AVIR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $176M AUM 123.21% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

BlackRock's AVIR Position: Q2 2026 in Review

BlackRock increased its Atea Pharmaceuticals (AVIR) stake by 3.4% in Q2 2026, buying an estimated $1.42M and bringing the position to 8,720,077 shares worth $40.5M. The position accounts for ﹤0.01% of the portfolio, ranked #2809.

BlackRock first reported a position in AVIR in Q4 2020 and has held it in 23 quarters since. The position peaked at $145M in Q3 2021. 125 funds tracked by Wall St. Rank hold AVIR as of Q2 2026.

  • BlackRock held 8,720,077 shares of Atea Pharmaceuticals worth $40.5M as of Q2 2026.
  • BlackRock bought 284,640 Atea Pharmaceuticals shares in Q2 2026, an estimated $1.42M.
  • Atea Pharmaceuticals made up ﹤0.01% of BlackRock's portfolio in Q2 2026, its #2809 holding.
  • BlackRock first reported a position in Atea Pharmaceuticals in Q4 2020 and has held it in 23 quarters since.
  • BlackRock's Atea Pharmaceuticals position peaked at $145M in Q3 2021.
  • 125 funds tracked by Wall St. Rank held Atea Pharmaceuticals as of Q2 2026.

Based on BlackRock's 13F filing for Q2 2026, filed 7 Aug 2026.